Blood Glycan Biomarkers in Women With Stage IV Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00897962|
Recruitment Status : Active, not recruiting
First Posted : May 12, 2009
Last Update Posted : January 18, 2018
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood glycan biomarkers in women with stage IV breast cancer.
|Condition or disease||Intervention/treatment|
|Breast Cancer||Other: Healthy Controls Other: Metastatic Breast Cancer Other: Non-cancer medical illness|
- To profile serum glycan biomarkers in women with metastatic stage IV breast cancer, healthy controls, and patients with noncancer medical illness.
- To determine whether serial serum glycan biomarkers correlate with response of metastatic disease to treatment.
OUTLINE: This is a multicenter study.
Blood is collected from patients with metastatic breast cancer, patients with noncancerous illness, and healthy volunteers. Samples are analyzed for serum glycan biomarkers by matrix-assisted laser desorption/ionization (MALDI) and Fourier transform ion-cyclotron resonance mass spectrometry (FT ICR MS) methods.
Blood samples are collected every 3 months for up to 18 months from patients with metastatic breast cancer. Patients without cancer have a single sample collected.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Serum Glycan Analysis in Breast Cancer|
|Study Start Date :||September 2006|
|Actual Primary Completion Date :||February 2011|
|Estimated Study Completion Date :||October 2018|
Metastatic Breast Cancer
Patients with metastatic breast cancer receiving treatment with chemotherapy, endocrine therapy or targeted therapy
Other: Metastatic Breast Cancer
Blood samples will be drawn every 3 months, for up to 18 months.
Non-cancer medical illness
Patients with non-cancer medical condition
Other: Non-cancer medical illness
One blood draw (2 teaspoons)
Healthy patients being seen for an annual exam
Other: Healthy Controls
One blood draw (2 teaspoons)
- Profiling serum glycan biomarkers in patients with metastatic breast cancer, healthy controls, and patients with noncancer medical illness [ Time Frame: up to 18 months ]
- Predictability of serial serum biomarkers in determining disease response and/or progression [ Time Frame: Up to 18 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00897962
|United States, California|
|University of California Davis Cancer Center|
|Sacramento, California, United States, 95817|
|Study Chair:||Helen K. Chew, MD||University of California, Davis|